By Fineline Cube 
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA: 688336), a China-based company, released its 2025 third-quarter report on October 24, 2025. In the first three quarters of 2025, the company achieved an operating revenue of RMB 1.116 billion, representing a year-on-year (YOY) increase of 18.80%. Net profit attributable to the parent company reached RMB 399 million, marking a substantial YOY growth of 71.15%.
R&D Progress
By the end of the third quarter of 2025, Sunshine Guojian reported significant R&D advancements:
- Anti-IL-17A mAb (608): NDA accepted for moderate-to-severe plaque psoriasis; Phase III trial for Ankylosing Spondylitis ongoing; Phase II trial for non-radiographic axial spondyloarthritis achieved positive results.
- Anti-IL-5 mAb (610): Phase III trial for severe eosinophilic asthma ongoing; Phase II trial for extended dosing interval in adults ongoing.
- Anti-IL-4Rα mAb (611): Phase III trial for moderate-to-severe atopic dermatitis met primary endpoint; Phase III trial for chronic rhinosinusitis with nasal polyps completed; Phase III trial for COPD ongoing.
- Recombinant Anti-IL-1β mAb (613): NDA submitted and accepted for acute gouty arthritis; Phase II study for intercritical gouty arthritis completed with positive results.
- Recombinant Anti-BDCA2 mAb (626): Phase Ib/II trial for Systemic Lupus Erythematosus (SLE) underway.
- Recombinant Anti-TL1A mAb (627): Phase I trial for Ulcerative Colitis (UC) underway.
Partnership Highlight
In July 2025, 3SBio Sunshine Guojian and 3SBio signed an exclusive licensing agreement with Pfizer, granting Pfizer global development and commercialization rights for SSGJ-707. The deal included a USD 1.4 billion upfront payment, setting a new record for Chinese innovative drug out-licensing transactions, with a total potential value exceeding USD 6 billion.-Fineline Info & Tech